Straits Times Index
3,318.53 +10.63 (+0.32%) Nikkei
39,103.22 +486.12 (+1.26%) Hang Seng
18,865.34 -330.26 (-1.72%) FTSE 100
8,370.33 -46.12 (-0.55%) Bitcoin USD
69,404.84 -465.12 (-0.67%) CMC Crypto 200
1,510.60 +7.94 (+0.53%)
GRI Bio, Inc. (GRI)
After hours:
| Previous close | 0.4145 |
| Open | 0.4182 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.4020 - 0.4699 |
| 52-week range | 0.3750 - 48.9300 |
| Volume | |
| Avg. volume | 257,174 |
| Market cap | 1.714M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
Data recently presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on Autoimmunity Company reiterates 2024 as year of data Click here to watch the “What This Means” segment LA JOLLA, CA, May 22, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoi
- GlobeNewswire
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
Data presented at the 14th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV® (nintedanib), a leading tyrosine kinase inhibitor with 2025 projected sales of $5 billion1 Company targeting IND filing for GRI-0803 in Q3 2024 with topline data expected Q4 2024 LA JOLLA, CA, May 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Kill
- GlobeNewswire
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score and total lung inflammation Company advancing Phase 2a biomarker study of GRI-0621 in patients with IPF with interim data expected Q3 2024 and topline data in Q4 2024 Data presented at the 2024 American Thoracic Society International Conference LA JOLLA, CA, May 20, 2024 (GLOBE NEWSWIRE) -- GRI Bio,
